奥贝胆酸NASH终于折戟。
$Intercept制药(ICPT)$ 公司重组重新定位。
ICPT Announces Restructuring.
To discontinue all NASH-related investments and reduce workforce by one-third.
Will continue its investment to support Ocaliva.
Cash, cash equivalents, restricted cash $435M
| 发布于: | Android | 转发：0 | 回复：0 | 喜欢：0 |
奥贝胆酸NASH终于折戟。
$Intercept制药(ICPT)$ 公司重组重新定位。
ICPT Announces Restructuring.
To discontinue all NASH-related investments and reduce workforce by one-third.
Will continue its investment to support Ocaliva.
Cash, cash equivalents, restricted cash $435M